Vaccine deals: India, Oxford-AstraZeneca numbers dip, but still on top; Pfizer gains most

Analysis of contracts countries are signing with vaccine makers for advance booking of candidates shows that the deals are still fluid, changing in a matter of days with some companies gaining and some losing orders given that most candidates are still in trial stage.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/38gdEZd
via IFTTT